Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:SRPT
Date1/2000
Raised
Post IPO Valuation

General Information

Websitesareptatherapeuti...
CategoryBioTech
Phone617-444-8424
Emailsarepta@sareptath...
Employees

Offices

Cambridge, USA
245 First Street
Suite 1800
Cambridge, MA, 02142
USA

People

President and Chief Executive Officer
Senior Vice President of Technical Operations
Senior Vice President, Chief Medical Officer

Tags

Sarepta Therapeutics

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that include their lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases.

Recent Milestones

Videos

Screenshots

Sarepta Therapeutics screenshot
Above: Sarepta Therapeutics
Uploaded: 12/15/12

Stock Price

Sources

    Sarepta Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock (finance.yahoo.com) [edit]
Edit This Page
Last Edited 8/18/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy